We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Maryland Gov. Larry Hogan last week vetoed legislation that would have funded the state’s Prescription Drug Affordability Board, an independent body established last year to evaluate costly drugs and set price caps. Read More
California biotech firm Sorrento Therapeutics and New York City’s Mount Sinai Health System are teaming up to test and develop a triple antibody cocktail that could potentially treat or help prevent COVID-19. Read More
About 28 million doses of hydroxychloroquine were distributed from the Strategic National Stockpile last month and states are wondering what to do with their excess supply since studies have cast doubt on the drug’s benefit as a COVID-19 treatment. Read More
The Office of Special Counsel (OSC) has recommended that Rick Bright be temporarily reinstated to his position as director of HHS’ Biomedical Advanced Research and Development Authority. Read More
Three of the nation’s top medical experts heading up the nation’s response to COVID-19 are now in quarantine after being exposed to the coronavirus. Read More
Following widespread criticism of the federal government’s handling of COVID-19 treatment remdesivir, HHS released details on Saturday of its distribution plan of the drug, and said states will make the final call on which hospitals get the drug. Read More
Australia’s Therapeutic Goods Administration is conducting a postmarket review of face masks in response to concerns about the quality of some masks cleared for use during the coronavirus pandemic. Read More
Moderna, a frontrunner in the race to develop a COVID-19 vaccine, announced Thursday that its phase 3 study for the candidate could start by early summer. Read More
A failed study of nearly 1,400 COVID-19 patients taking hydroxychloroquine is the latest to cast doubt on the drug’s benefit as a coronavirus treatment. Read More
How the federal government is handling the distribution of Gilead’s remdesivir for treatment of COVID-19 patients is sparking outrage and sharp criticism from physicians’ groups and doctors across the nation. Read More